Biogen’s Diranersen Shows First Evidence of Tau Reduction and Cognitive Benefit in Early Alzheimer’s
Event summary
- Biogen’s Phase 2 CELIA study of diranersen (BIIB080) demonstrated robust reductions in tau pathology and cognitive benefits in early Alzheimer’s patients.
- The study showed slowing of clinical decline across all doses, particularly at the lowest dose (60 mg every 24 weeks).
- Diranersen’s safety and tolerability profile was consistent with previous Phase 1b study results.
- The study enrolled 416 participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia.
- Biogen plans to present the data at the Alzheimer’s Association International Conference (AAIC) 2026.
The big picture
Biogen’s Phase 2 CELIA study results mark a significant milestone in Alzheimer’s research, providing the first evidence that reducing tau pathology can meaningfully impact disease progression. The study’s findings could reshape the treatment landscape for early Alzheimer’s, as current therapies primarily target amyloid plaques. The success of diranersen could also validate the antisense oligonucleotide (ASO) approach, potentially opening new avenues for neurodegenerative disease treatments.
What we're watching
- Regulatory Pathway
- Whether Biogen can secure regulatory approval for diranersen based on the Phase 2 data and advance to registrational trials.
- Clinical Efficacy
- The extent to which the cognitive benefits observed in the Phase 2 study can be replicated in larger, longer-term studies.
- Competitive Landscape
- How Biogen’s tau-targeting approach will position diranersen against other emerging Alzheimer’s therapies.
Related topics